|

Carboplatin/Pemetrexed Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • University Hospital, Essen1
  • Phanes Therapeutics1

Indications

  • Lung Cancer2
  • Cancer2
  • Lung Cancer (NSCLC)1
  • Pancreatic Ductal Adenocarcinoma1
  • Non Small Cell Lung Cancer1

Other1 trial

Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
Phase 2

Huntersville, North Carolina1 trial

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Carolina BioOncology Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.